0.00
100.00%
-0.2071
Renalytix Plc Adr stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the common and costly chronic medical conditions globally. The company's product is KidneyIntelX which is being designed to make improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.
See More
Previous Close:
$0.2071
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$17.18M
Revenue:
$2.41M
Net Income/Loss:
$-42.50M
P/E Ratio:
0.00
EPS:
-1.1
Net Cash Flow:
$-36.15M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
Renalytix Plc Adr Stock (RNLX) Company Profile
Name
Renalytix Plc Adr
Sector
Industry
Phone
44 29 2071 0570
Address
FINSGATE, LONDON
Renalytix Plc Adr Stock (RNLX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-18-22 | Initiated | H.C. Wainwright | Buy |
Jan-04-22 | Initiated | BTIG Research | Buy |
Oct-04-21 | Initiated | Guggenheim | Buy |
Jul-02-21 | Initiated | Berenberg | Buy |
Aug-11-20 | Initiated | Stifel | Buy |
Renalytix Plc Adr Stock (RNLX) Latest News
Stock Market Recap: Renalytix Plc ADR (RNLX) Concludes at 0.21, a 5.66 Surge/Decline - The Dwinnex
What was Renalytix Plc ADR (RNLX)’s performance in the last session? - US Post News
Renalytix Plc ADR: A Year of Highs, Lows, and Market Resilience - The InvestChronicle
Ratios in Focus: Analyzing Renalytix Plc ADR (RNLX)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Renalytix AI stock hits 52-week low at $0.22 amid market challenges - Investing.com
Renalytix Plc ADR (RNLX)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
There is no way Renalytix Plc ADR (RNLX) can keep these numbers up - SETE News
How analysts predict Renalytix Plc ADR (RNLX) will perform this quarter? - US Post News
Renalytix Plc ADR (RNLX) Stock: Navigating a Year of Stock Volatility - The InvestChronicle
Investor’s Delight: Renalytix Plc ADR (RNLX) Closes Strong at 0.31, Up 7.31 - The Dwinnex
Renalytix Plc ADR (RNLX) Stock: The Story of a 52-Week Stock Range - The InvestChronicle
Analyzing RNLX’s price-to-book ratio for the last quarter - US Post News
Renalytix Plc ADR (RNLX) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle
Closing Figures: Renalytix Plc ADR (RNLX)’s Negative Finish at 0.31, Down -23.14 - The Dwinnex
Form 8.5 (EPT/RI)-Renalytix Plc - GlobeNewswire Inc.
Investing in Renalytix Plc ADR (RNLX) might be an excellent idea, but the stock is currently overvalued/undervalued - US Post News
Check out these key findings about Renalytix Plc ADR (RNLX) - SETE News
Renalytix Plc ADR Inc. (RNLX) Price Performance Over the Years: A Comparative Study - The InvestChronicle
What to expect from Renalytix Plc ADR’s (RNLX) current quarter earnings? - US Post News
Examining Renalytix Plc ADR (RNLX) more closely is necessary - US Post News
It is Poised to be a Bull Market for Renalytix Plc ADR (RNLX) - SETE News
Upward Trajectory: Renalytix Plc ADR (RNLX) Posts a Gaine, Closing at 0.34 - The Dwinnex
Is Renalytix Plc ADR (RNLX) a good investment opportunity? - US Post News
Renalytix Plc ADR Inc. (RNLX) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle
Renalytix AI shares hold buy rating from HC Wainwright - Investing.com
- Invest Chronicle - The InvestChronicle
Barclays raises Alkami Technology target to $31 on growth outlook By Investing.com - Investing.com India
Renalytix Partners with Steno for Kidney Care in Europe - Investing.com
Did Renalytix Plc ADR (RNLX) perform well in the last session? – US Post News - US Post News
Market Watch Highlights: Renalytix Plc ADR (RNLX) Ends on an Upturn Note at 0.25 – DWinneX - The Dwinnex
Investing in Renalytix Plc ADR (RNLX) might be an excellent idea, but the stock is currently overvalued/undervalued ... - US Post News
Check out these key findings about Renalytix Plc ADR (RNLX) – Sete News - SETE News
Post-Trade Analysis: Renalytix Plc ADR (RNLX) Slides -28.97, Closing at 0.25 – DWinneX - The Dwinnex
Renalytix Submits Hearing Request to Nasdaq Hearings Panel in Regard to Staff Delisting Determination - Yahoo Finance UK
Renalytix Plc ADR (RNLX) Stock: A Year of Market Movement, Down and Up - The InvestChronicle
Renalytix Plc Share Chat (RENX) - London South East
Cummins raises dividend as streak continues By Investing.com - Investing.com
Renalytix faces delisting from Nasdaq over noncompliance - Investing.com India
Renalytix appoints CohnReznick as new auditor By Investing.com - Investing.com
Renalytix plc successful completion of $30.0 million financing package - The Globe and Mail
Is it possible to buy Renalytix Plc ADR(RNLX) shares at a good price now? – US Post News - US Post News
Renalytix AI plc Issue of Shares Under the 2020 Employee Share Purchase Plan, PDMR Dealing and Total Voting Rights - The Globe and Mail
Renalytix to Report Second Quarter and First Half Fiscal Year 2022 Financial Results on March 31 - The Globe and Mail
Renalytix to Present at the 2021 Wells Fargo Virtual Healthcare Conference - The Globe and Mail
Renalytix Reports Financial Results for First Quarter of Fiscal Year 2022 - The Globe and Mail
Renalytix to Present at BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference - The Globe and Mail
Renalytix Appoints Ann Berman to its Board of Directors - The Globe and Mail
RNLX’s Market Whiplash: 40.54% YTD Rise, -3.33% Plunge in 30 Days - The InvestChronicle
Medicare sets $950 price for Renalytix kidney test By Investing.com - Investing.com
Renalytix Plc Share Chat. Chat About RENX SharesStock Quote, Charts, Trade History, Share Chat, Financial Terms ... - London South East
Medicare sets $950 price for Renalytix kidney test - Investing.com
Renalytix Plc Adr Stock (RNLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):